TCT Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
DES draft guidance in signature stage: FDA hopes to release a draft of its new drug-eluting stent guidance document within the next few weeks, CDRH Director Dan Schultz says Oct. 23 at the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. The highly anticipated two-part document is over 100 pages long, covering chemistry manufacturing controls and safety evaluation of the eluting drug, animal and biocompatibility studies, non-clinical bench testing, and new recommended designs for pre- and postmarket clinical studies (1"The Gray Sheet" March 12, 2007, p. 3). FDA will host a public workshop to solicit feedback once the draft is released
You may also be interested in...
Will FDA’s New Requirements For Drug-Eluting Stents Impact Innovation?
Shifting regulatory requirements are compelling medical device companies, both big and small, to be more prudent with their R&D dollars
Will FDA’s New Requirements For Drug-Eluting Stents Impact Innovation?
Shifting regulatory requirements are compelling medical device companies, both big and small, to be more prudent with their R&D dollars
Xtent Aims For Long-Lesion Indication For Its Custom NX Drug-Eluting Stent
Buoyed by recent European clinical trial results, drug-eluting stent developer Xtent expects to begin a U.S. pivotal trial later this year in support of an indication no other drug-eluting coronary stent company has: treatment of long lesions and multiple lesions